Orchestra BioMed Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.5 | $2.6 | $2.8 | $3.5 | — |
| Operating income | -$51.8 | -$64.3 | -$51.5 | -$32.7 | -$0.4 |
| Net income | -$52.7 | -$61.0 | -$49.1 | -$33.6 | -$0.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$49.5 | -$50.8 | -$46.2 | -$29.9 | — |
| Dividends | — | — | — | $20.0 | — |
Shares outstanding 60.1M · Free float 39.8%
Annual filing data through FY ended December 31, 2025; float as of October 14, 2026.
Orchestra BioMed Kept Its Revised Hypertension Trial Timetable